Literature DB >> 17367874

Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.

Jacqueline C Ruiz1, James R Beadle, Kathy A Aldern, Kathy A Keith, Caroll B Hartline, Earl R Kern, Karl Y Hostetler.   

Abstract

Esterification of cidofovir (CDV), an antiviral nucleoside phosphonate, with alkyl or alkoxyalkyl groups increases antiviral activity by enhancing cell uptake and conversion to CDV diphosphate. Hexadecyloxypropyl-CDV (HDP-CDV) has been shown to be 40-100 times more active than CDV in vitro in cells infected with herpes group viruses, variola, cowpox, vaccinia or ectromelia viruses. Since the first phosphorylation of CDV may be rate limiting, we synthesized the hexadecyloxypropyl-phosphate (HDP-P-) and octadecyloxyethyl-phosphate (ODE-P-) conjugates of CDV and phosphonomethoxy-ethyl-adenine (PMEA, adefovir). We tested the CDV analogs in cells infected with human cytomegalovirus, herpes simplex virus, cowpox virus and vaccinia virus; the analogs of PMEA were tested in cells infected with the human immunodeficiency virus, type 1. In general, the alkoxyalkyl-phosphate conjugates of CDV were substantially more active than CDV. HDP-P-CDV and ODE-P-CDV were 4.6-40 times more active against HCMV and 7-30 times more active against cowpox and vaccinia in vitro. Although the compounds of this type were more cytotoxic than the unmodified bases, their selectivity for virally infected cells was generally greater than the parent nucleotides except that HDP-P-PMEA showed little or no selectivity in HIV-1 infected MT-2 cells. Although the new compounds with an interposed phosphate were generally less active than the corresponding alkoxyalkyl esters of CDV and PMEA, the present approach provides a possible alternative method for enhancing the antiviral activity of drugs of this class.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17367874      PMCID: PMC1899528          DOI: 10.1016/j.antiviral.2006.09.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

1.  Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism.

Authors:  Kathy A Aldern; Stephanie L Ciesla; Kristine L Winegarden; Karl Y Hostetler
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

2.  Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.

Authors:  James R Beadle; Caroll Hartline; Kathy A Aldern; Natalie Rodriguez; Emma Harden; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

3.  Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.

Authors:  Earl R Kern; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.

Authors:  Deborah J Bidanset; James R Beadle; W Brad Wan; Karl Y Hostetler; Earl R Kern
Journal:  J Infect Dis       Date:  2004-07-01       Impact factor: 5.226

5.  Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

Authors:  R Mark Buller; Gelita Owens; Jill Schriewer; Lora Melman; James R Beadle; Karl Y Hostetler
Journal:  Virology       Date:  2004-01-20       Impact factor: 3.616

6.  Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.

Authors:  Kathy A Keith; William B Wan; Stephanie L Ciesla; James R Beadle; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells.

Authors:  M C Connelly; B L Robbins; A Fridland
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

8.  Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

Authors:  Debra C Quenelle; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

9.  Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro.

Authors:  K Y Hostetler; G D Kini; J R Beadle; K A Aldern; M F Gardner; R Border; R Kumar; L Barshak; C N Sridhar; C J Wheeler; D D Richman
Journal:  Antiviral Res       Date:  1996-06       Impact factor: 5.970

10.  Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.

Authors:  H T Ho; K L Woods; J J Bronson; H De Boeck; J C Martin; M J Hitchcock
Journal:  Mol Pharmacol       Date:  1992-01       Impact factor: 4.436

View more
  5 in total

Review 1.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

Review 2.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

3.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

Authors:  Karl Y Hostetler
Journal:  Antiviral Res       Date:  2009-05       Impact factor: 5.970

4.  Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs.

Authors:  Don B Gammon; Robert Snoeck; Pierre Fiten; Marcela Krecmerová; Antonín Holý; Erik De Clercq; Ghislain Opdenakker; David H Evans; Graciela Andrei
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

5.  A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy.

Authors:  Jae Suk Kim; James R Beadle; William R Freeman; Karl Y Hostetler; Kathrin Hartmann; Nadejda Valiaeva; Igor Kozak; Laura Conner; Julissa Trahan; Kathy A Aldern; Lingyun Cheng
Journal:  Mol Vis       Date:  2012-07-14       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.